Literature DB >> 21373779

ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer.

Renty B Franklin1, Bernard A Levy, Jing Zou, Nader Hanna, Mohamed Mokhtar Desouki, Omar Bagasra, Leslie A Johnson, Leslie C Costello.   

Abstract

PURPOSE: Hepatocellular cancer (HCC) is a deadly and most rapidly increasing cancer in the USA and worldwide. The etiology and factors involved in development of HCC remain largely unknown. A marked decrease in zinc occurs in HCC. Its role and involvement in HCC has not been identified. We investigated the relationship of cellular zinc changes to the development of malignancy, and the identification of potential zinc transporters associated with the inability of hepatoma cells to accumulate zinc.
METHODS: The detection of relative zinc levels in situ in normal hepatic cells vs. hepatoma was performed on normal and HCC tissue sections. ZIP1, 2, 3, and 14 transporters were identified by immunohistochemistry.
RESULTS: Intracellular zinc levels are markedly decreased in HCC hepatoma cells vs. normal hepatic cells in early stage and advanced stage malignancy. ZIP14 transporter is localized at the plasma membrane in normal hepatocytes, demonstrating its functioning for uptake and accumulation of zinc. The transporter is absent in the hepatoma cells and its gene expression is downregulated. The change in ZIP14 is concurrent with the decrease in zinc. ZIP1, 2, 3 are not associated with normal hepatocyte uptake of zinc, and HCC zinc depletion. HepG2 cells exhibit ZIP14 transporter. Zinc treatment inhibits their growth.
CONCLUSIONS: ZIP14 downregulation is likely involved in the depletion of zinc in the hepatoma cells in HCC. These events occur early in the development of malignancy possibly to protect the malignant cells from tumor suppressor effects of zinc. This provides new insight into important factors associated with HCC carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21373779      PMCID: PMC3724761          DOI: 10.1007/s12029-011-9269-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  25 in total

1.  Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands.

Authors:  Leslie A Johnson; Mazhar A Kanak; Andre' Kajdacsy-Balla; Joseph P Pestaner; Omar Bagasra
Journal:  Methods       Date:  2010-08-10       Impact factor: 3.608

2.  Zinc toxicity alters mitochondrial metabolism and leads to decreased ATP production in hepatocytes.

Authors:  Joseph Lemire; Ryan Mailloux; Vasu D Appanna
Journal:  J Appl Toxicol       Date:  2008-03       Impact factor: 3.446

3.  Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response.

Authors:  Juan P Liuzzi; Louis A Lichten; Seth Rivera; Raymond K Blanchard; Tolunay Beker Aydemir; Mitchell D Knutson; Tomas Ganz; Robert J Cousins
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-29       Impact factor: 11.205

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Metallothionein expression and concentrations of copper and zinc are associated with tumor differentiation in hepatocellular carcinoma.

Authors:  T Tashiro-Itoh; T Ichida; Y Matsuda; T Satoh; M Sugiyama; Y Tanaka; T Ishikawa; S Itoh; M Nomoto; H Asakura
Journal:  Liver       Date:  1997-12

6.  Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14.

Authors:  K M Taylor; H E Morgan; A Johnson; R I Nicholson
Journal:  FEBS Lett       Date:  2005-01-17       Impact factor: 4.124

7.  Interleukin-1beta contributes via nitric oxide to the upregulation and functional activity of the zinc transporter Zip14 (Slc39a14) in murine hepatocytes.

Authors:  Louis A Lichten; Juan P Liuzzi; Robert J Cousins
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-29       Impact factor: 4.052

8.  Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration.

Authors:  Benjamin P Weaver; Yuxia Zhang; Stephen Hiscox; Grace L Guo; Udayan Apte; Kathryn M Taylor; Christian T Sheline; Li Wang; Glen K Andrews
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

Review 9.  Trace element concentration in metastatic liver disease: a systematic review.

Authors:  K Gurusamy; B R Davidson
Journal:  J Trace Elem Med Biol       Date:  2007-05-07       Impact factor: 3.849

Review 10.  Liver-cell dysplasia and hepatocellular carcinoma.

Authors:  M Podda; M Roncalli; P M Battezzati; M Borzio; S Bruno; E Servida; G Coggi
Journal:  Ital J Gastroenterol       Date:  1992-01
View more
  28 in total

Review 1.  Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: an enigma and an opportunity.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

Review 2.  Zinc and liver disease.

Authors:  Mohammad K Mohammad; Mohammad K Mohommad; Zhanxiang Zhou; Matthew Cave; Ashutosh Barve; Craig J McClain
Journal:  Nutr Clin Pract       Date:  2012-02       Impact factor: 3.080

Review 3.  Physiologic implications of metal-ion transport by ZIP14 and ZIP8.

Authors:  Supak Jenkitkasemwong; Chia-Yu Wang; Bryan Mackenzie; Mitchell D Knutson
Journal:  Biometals       Date:  2012-02-09       Impact factor: 2.949

Review 4.  The status of zinc in the development of hepatocellular cancer: an important, but neglected, clinically established relationship.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

5.  Resveratrol-zinc combination for prostate cancer management.

Authors:  Chandra K Singh; Anna Pitschmann; Nihal Ahmad
Journal:  Cell Cycle       Date:  2014-05-27       Impact factor: 4.534

Review 6.  Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Expert Opin Ther Targets       Date:  2016-12-05       Impact factor: 6.902

7.  Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.

Authors:  Lu Zhang; Xiaoqiao Liu; Xuegong Zhang; Ronghua Chen
Journal:  Mol Genet Genomics       Date:  2015-12-28       Impact factor: 3.291

8.  Hepatic ZIP8 deficiency is associated with disrupted selenium homeostasis, liver pathology, and tumor formation.

Authors:  Liu Liu; Xiangrong Geng; Yihong Cai; Bryan Copple; Masafumi Yoshinaga; Jian Shen; Daniel W Nebert; Hua Wang; Zijuan Liu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-21       Impact factor: 4.052

9.  A Review of the Current Status and Concept of the Emerging Implications of Zinc and Zinc Transporters in the Development of Pancreatic Cancer.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Pancreat Disord Ther       Date:  2013

10.  In situ clinical evidence that zinc levels are decreased in breast invasive ductal carcinoma.

Authors:  Leslie C Costello; Jing Zou; Renty B Franklin
Journal:  Cancer Causes Control       Date:  2016-04-20       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.